Cell Identity Loss

Altos Labs

AUDIT: Altos Labs: Senolytic Insolvency, and the $3 Billion Biological Debt

A forensic audit of Altos Labs' $3B longevity pivot. Explore the biological reality of epigenetic reprogramming, senolytic insolvency, and FDA roadblocks.